Atea anticipates Phase III C-BEYOND midyear and C-FORWARD year-end readouts while projecting cash runway through 2027
Atea Pharmaceuticals, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.38
-9.4% in 3d after detection
Post-detection moves
1h
—
1d
-6.6%
3d
-9.4%
7d
-3.3%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS